TRPV1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL86240	1.00	18/20
SCHEMBL60880	0.49	13/20
SCHEMBL44847	0.53	12/20
SCHEMBL58722	0.51	12/20
SCHEMBL44846	0.50	12/20
SCHEMBL42296	0.55	10/20
SCHEMBL42297	0.55	10/20
SCHEMBL47276	0.55	10/20
SCHEMBL89354	0.53	10/20
SCHEMBL84835	0.49	10/20
Capsaicin (SCHEMBL8085)	1.00	9/20
Capsaicin (SCHEMBL8086)	1.00	9/20
Zucapsaicin (SCHEMBL41210)	1.00	9/20
Nonivamide (SCHEMBL81939)	0.93	9/20
SCHEMBL28491	0.55	9/20
SCHEMBL42722	0.50	9/20
SCHEMBL43706	0.50	9/20
SCHEMBL57332	0.59	8/20
SCHEMBL57333	0.55	8/20
SCHEMBL6198	0.54	8/20

Clinical trials — most relevant to TRPV1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
TRPV Expression in Subjects With Sensitive Skin	PHASE4	UNKNOWN
Cervical Capsaicin for Labor Induction and Pain Relief	PHASE4	WITHDRAWN
Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls	PHASE4	COMPLETED
Oliceridine vs Sufentanil for Cough During Anesthesia Induction	PHASE4	NOT_YET_RECRUITING
Botulinum Toxin Injections for Oral Neuropathic Pain	PHASE3	COMPLETED
Influence on Cough and Airway Symptoms by Oral Capsaicin	PHASE2	ACTIVE_NOT_RECRUITING
Palmitoylethanolamide for Chronic Inflammatory Pain Conditions	PHASE2	RECRUITING
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy	PHASE2	RECRUITING
Efficacy of OnabotulinumtoxinA in Migraine	PHASE2	COMPLETED
Do Acid Sensing Ion Channels Contribute to Heartburn?	PHASE1	COMPLETED
Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC	PHASE1	COMPLETED
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases	PHASE1	COMPLETED
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8	EARLY_PHASE1	COMPLETED
Mechanisms of Human Heat Perception - Involvement of TRPA1, TRPV1 and TRPM3	EARLY_PHASE1	COMPLETED
Menthol Stimulation of Brown Adipose Tissue in Humans: Aim 1	EARLY_PHASE1	RECRUITING
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy	nan	ENROLLING_BY_INVITATION
Neurogenic Mechanisms in Burning Mouth Syndrome	nan	COMPLETED
Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin	nan	ENROLLING_BY_INVITATION
Effect of Boswellia Serrata on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers	nan	RECRUITING
Dissecting the Heterogeneity of Oral Cancer Pain	nan	UNKNOWN
Relationship Between Polymorphisms of TRPV1 and KCC2 Gene in Children With Febrile Seizures	nan	COMPLETED
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.	nan	COMPLETED
Nutrition for Migraine Prevention	nan	COMPLETED
Efficacy and Safety of a Novel Monopolar Radiofrequency Device for Mid and Lower Face Rejuvenation	nan	COMPLETED
A Mechanistic Evaluation of the Nociceptive Desensitizing Properties of Topical Capsaicin	nan	COMPLETED
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers	nan	COMPLETED
A Study on the Mechanism of Cough Hypersensitivity	nan	UNKNOWN
An Investigation Into the Mechanism of Inhalation Cough Challenge	nan	COMPLETED
Double-blind Trial of Mannitol Cream to Block the Effect of Capsaicin Cream	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TRPV1 binder may also engage these)

Protein	Name	Similarity
Q704Y3	—	1.000	Q704Y3 →
Q6RX08	—	1.000	Q6RX08 →
Q6R5A3	—	1.000	Q6R5A3 →
A0A1D5PXA5	—	1.000	A0A1D5PXA5 →
Q9ERZ8	—	1.000	Q9ERZ8 →
Q9EPK8	—	1.000	Q9EPK8 →
O35433	—	1.000	O35433 →
Q697L1	—	1.000	Q697L1 →
Q8K424	—	1.000	Q8K424 →
TRPV4	Transient receptor potential cation channel subfamily V member 4	1.000	landscape →
TRPV3	Transient receptor potential cation channel subfamily V member 3	0.998	landscape →
Q9R186	—	0.998	Q9R186 →
Q9XSM3	—	0.997	Q9XSM3 →
Q9QUQ5	—	0.996	Q9QUQ5 →
P69744	—	0.995	P69744 →
Q9WUD2	—	0.995	Q9WUD2 →
Q9MYV9	—	0.995	Q9MYV9 →
P19334	—	0.995	P19334 →
Q91WD2	—	0.995	Q91WD2 →
Q9JIP0	—	0.994	Q9JIP0 →
P79100	—	0.994	P79100 →
P48994	—	0.993	P48994 →
TRPC5	Short transient receptor potential channel 5	0.993	landscape →
P34586	—	0.993	P34586 →
Q9QX29	—	0.993	Q9QX29 →
TRPV2	Transient receptor potential cation channel subfamily V member 2	0.993	landscape →
D3YWQ0	—	0.993	D3YWQ0 →
Q9WTR1	—	0.993	Q9WTR1 →
Q61056	—	0.992	Q61056 →
Q5ICL9	—	0.992	Q5ICL9 →